
Sign up to save your podcasts
Or
Once pharma’s oncology powerhouse, Roche is charting a new course that extends beyond its traditional stronghold in cancer therapeutics. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how the Swiss pharma has reshaped its strategy for long-term growth. They also discuss another tumultuous weekend for staff at FDA and NIH, as well as the challenges of precision medicine for psychiatric conditions.
View full story: https://www.biocentury.com/article/655157
00:00 - Introduction
00:45 - Roche Reboot
08:47 - Precision Medicine in Psychiatry
13:07 - 5 Things on Trump 2.0
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].
Reach us by sending a text
4.9
2828 ratings
Once pharma’s oncology powerhouse, Roche is charting a new course that extends beyond its traditional stronghold in cancer therapeutics. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how the Swiss pharma has reshaped its strategy for long-term growth. They also discuss another tumultuous weekend for staff at FDA and NIH, as well as the challenges of precision medicine for psychiatric conditions.
View full story: https://www.biocentury.com/article/655157
00:00 - Introduction
00:45 - Roche Reboot
08:47 - Precision Medicine in Psychiatry
13:07 - 5 Things on Trump 2.0
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].
Reach us by sending a text
763 Listeners
2,184 Listeners
39 Listeners
123 Listeners
317 Listeners
60 Listeners
88 Listeners
146 Listeners
10 Listeners
38 Listeners
154 Listeners
3 Listeners
12 Listeners
45 Listeners
11 Listeners